论文部分内容阅读
66例慢性乙型肝炎患者,分阿昔洛韦(acyclocir)、白细胞干扰素与保肝药物治疗对照,以血清HBeAg、HBcAg、DNA-P 和HBV-DNA 四项乙肝病毒(HBV)复制标志考核疗效,治疗后经1年随访观察,在阿昔洛韦姐,每项HBV 复制标志阴转率与对照组各项比较,其差异性均显著,干扰素组只有HBcAg 阴转率与对照组相比较有显著性差异,而两组1年随访四项HBV 复制标志全阴病例数与对照组比较,均有显著性差异.
Sixty-six patients with chronic hepatitis B were divided into two groups: acyclocir, leukocyte interferon and hepatoprotective drugs. Four HBsAg, HBcAg, DNA-P and HBV-DNA replication markers were tested Curative effect. After 1-year follow-up after treatment, in acyclovir sister, the difference of each negative rate of HBV replication markers compared with the control group was significant. Only the HBcAg negative conversion rate in the interferon group was significantly lower than that in the control group There were significant differences between the two groups of one year follow-up of four HBV replication markers of all cases of yin and control groups, there were significant differences.